Becton, Dickinson & Stock

$169.97

0.54% yesterday

NYSE, Jun 26, 10:10 pm CET

ISIN

US0758871091

Symbol

BDX

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Becton, Dickinson & Stock price

$169.97

-57.75 25.36% 5Y

NYSE, Closing price Thu, Jun 26 2025

-0.93 0.54%

ISIN

US0758871091

Symbol

BDX

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$48.7b

Enterprise Value

$67.3b

Net debt

$18.6b

Cash

$683.0m

Shares outstanding

286.6m

Valuation (TTM | estimate)

P/E

32.25 | 11.86

P/S

2.33 | 2.21

EV/Sales

3.23 | 3.05

EV/FCF

25.98

P/B

1.93

Dividends

DPS

$3.80

Yield 1Y | 5Y

2.24% | 1.40%

Growth 1Y | 5Y

4.40% | 4.82%

Payout 1Y | 3Y

64.85% | 65.25%

Increased

25 Years

Financials (TTM | estimate)

Revenue

$20.9b | $22.0b

EBITDA

$5.1b | $6.4b

EBIT

$2.7b

Net Income

$1.5b | $4.1b

Free Cash Flow

$2.6b

Growth (TTM | estimate)

Revenue

5.84% | 9.26%

EBITDA

-0.88% | 24.15%

EBIT

-4.35%

Net Income

15.25% | 140.84%

Free Cash Flow

-14.35%

Margin (TTM | estimate)

Gross

44.64%

EBITDA

24.42% | 29.24%

EBIT

13.06%

Net

7.28% | 18.62%

Free Cash Flow

12.42%

EPS

$5.27

FCF per Share

$9.04

Short interest

1.10%

Employees

74.00k

Rev per Employee

$270.00k

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Get Started for Free Today

Becton, Dickinson & Stock Analysis

Unlock Scores for Free

??

21 Analysts have issued a Becton, Dickinson & forecast:

10x Buy

48%

11x Hold

52%

More details on Analyst Estimates Including Price Targets

21 Analysts have issued a Becton, Dickinson & forecast:

Buy

48%

Hold

52%

Analyst Estimates with Stock Price Targets

Financial data from Becton, Dickinson &

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	20,867 20,867	6% 6% 100%
- Direct Costs	11,553 11,553	6% 6% 55%
Gross Profit	9,314 9,314	6% 6% 45%
- Selling and Administrative Expenses	5,043 5,043	7% 7% 24%
- Research and Development Expense	1,246 1,246	6% 6% 6%
EBITDA	5,095 5,095	1% 1% 24%
- Depreciation and Amortization	2,369 2,369	3% 3% 11%
EBIT (Operating Income) EBIT	2,726 2,726	4% 4% 13%
Net Profit	1,519 1,519	15% 15% 7%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Becton, Dickinson & Stock News

Positive

Seeking Alpha

●

3 days ago

Best Dividend Kings: June 2025

Dividend Kings have underperformed the S&P 500 year-to-date, but 26 are outperforming SPY in 2025, with 32 posting positive returns. Dividend growth remains healthy, with four recent increases and a collective 2025 growth rate of 5.19%, despite some downward earnings revisions. Seventeen Dividend Kings appear undervalued and offer long-term annualized expected returns of at least 10%, based on ...

Neutral

Seeking Alpha

●

17 days ago

Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Becton, Dickinson and Company (NYSE:BDX ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Call Participants Robert Justin Marcus - JPMorgan Chase & Co, Research Division Unidentified Analyst Yes.

Positive

Seeking Alpha

●

18 days ago

Becton, Dickinson: A Dividend King Facing Challenges Offers Value

Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth sup...

More Becton, Dickinson & News

Company Profile

Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.

Head office	United States
CEO	Thomas Polen
Employees	74,000
Founded	1897
Website	www.bd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now